A panel of experts on colorectal cancer provides comprehensive insights on MRD testing within the disease space, highlight the general landscape, recent data, ongoing trials, and future directions.
EP. 1: Treating Colorectal Cancer: Overview of MRD Testing and ctDNA
A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.
EP. 2: When is MRD Testing Performed in Colorectal Cancer Treatment?
Experts on colorectal cancer discuss the timing of testing for minimal residual disease in the treatment journey.
EP. 3: MRD Testing Platforms in Colorectal Cancer
Colorectal cancer specialists discuss MRD testing platforms and how to choose among the available testing assays.
EP. 4: Testing for MRD in Colorectal Cancer
Focusing on the adjuvant setting, the expert panel discusses the timing and frequency of MRD testing in patients with colorectal cancer.
EP. 5: Colorectal Cancer: MRD Testing in the Community Setting
Pashtoon Murtaza Kasi, MD, MS, discusses MRD testing practices in the community oncology setting and provides recommendations on the integration of MRD testing into clinical practice.
EP. 6: Practical Considerations in MRD Testing in CRC
Experts on colorectal cancer discuss practical considerations related to MRD testing, highlighting strategies to navigate potential challenges.
EP. 7: Evolution of MRD Testing in Colorectal Cancer
The panel discusses how MRD testing has evolved as a clinical tool in colorectal cancer, highlighting the phase 2/3 COBRA study and its implications.
EP. 8: Patient Profile: A 52-Year-Old Woman With Colorectal Cancer
John L. Marshall, MD, presents the case of a 52-year-old woman with mid-rectal carcinoma, and the panel offers its initial impressions.
EP. 9: Colorectal Cancer: Updates from the GALAXY Arm in CIRCULATE-Japan
Focusing on the GALAXY arm in the CIRCULATE-Japan study, experts on colorectal cancer discuss how recent data are informing the evolving treatment landscape.
EP. 10: BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer
Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.
EP. 11: Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD
Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.
EP. 12: Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer
Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.
EP. 13: Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer
The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.
EP. 14: Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2
The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.
EP. 15: CIRCULATE-NORTH AMERICA and Barriers to Enrollment
Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.
EP. 16: MRD Testing in CRC: Gaps in our Understanding and Potential Advancements
The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.
EP. 17: Trajectory of CRC Treatment Landscape
The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer